Biotech Dilemma: When a Loan Isn't Non-Dilutive

On this week's episode of Biotech Banter, we've got three related tweets about Retrophin's (NASDAQ: RTRX  ) announcement last week to take out a convertible note to help pay for its license of an orphan drug called Thiola from Mission Pharmacal.

While technically a non-dilutive financing that keeps investors' equity the same, multiple people on Twitter jumped in, pointing out that it's only non-dilutive if the company has money to pay back the loan at the end of the term. Otherwise, the lender will be repaid with shares of the company's stock.

Paying back a loan isn't a problem for companies that meet their revenue expectations. Unfortunately, there are plenty of examples of biotechs, such as Dendreon (NASDAQOTH: DNDNQ  ) , where the lofty goals were never met. Dendreon has more than half a billion dollars in long-term debt on its balance sheet and still isn't profitable.

One way to avoid the dilemma of either taking out a loan, or diluting shareholder value though secondary offerings, is to find companies that have assets they can sell to slow the cash burn. Senior biotech specialist Brian Orelli highlights two in the video below: Seattle Genetics (NASDAQ: SGEN  ) , which licenses out rights to use its antibody payload to other companies, and Regeneron Pharmaceuticals (NASDAQ: REGN  ) , which has a deal with Sanofi to pay a large chunk of its R&D costs.

Or you could just invest in drugmakers with so much cash they hand it out to investors every quarter
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2984672, ~/Articles/ArticleHandler.aspx, 8/29/2015 11:53:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.03 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: **
REGN $536.70 Down -1.30 -0.24%
Regeneron Pharmace… CAPS Rating: ***
RTRX $27.84 Up +0.39 +1.42%
Retrophin, Inc. CAPS Rating: **
SGEN $42.25 Up +1.01 +2.45%
Seattle Genetics CAPS Rating: ***